Valuation: Jasper Therapeutics, Inc.

Market Cap 21.67M 18.87M 17.86M 16.23M 30.32M 2.08B 30.47M 213M 82.27M 1.05B 81.4M 79.59M 3.38B P/E 2026 *
-1.16x
P/E 2027 * -0.69x
Enterprise Value -128M -111M -105M -95.52M -178M -12.21B -179M -1.25B -484M -6.21B -479M -468M -19.87B EV / Sales 2026 *
-53.1x
EV / Sales 2027 * -
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jasper Therapeutics, Inc.

1 day+10.52%
Current month-17.17%
3 months+36.00%
6 months-48.71%
Current year-64.97%
Current year 0.32
Extreme 0.3151
2.07
1 year 0.32
Extreme 0.3151
2.69
3 years 0.32
Extreme 0.3151
31.01
5 years 0.32
Extreme 0.3151
188.8
10 years 0.32
Extreme 0.3151
188.8
Manager TitleAgeSince
Chief Executive Officer 54 05/01/2026
Director of Finance/CFO 54 21/09/2023
Chief Operating Officer 59 15/07/2026
Director TitleAgeSince
Director/Board Member 54 05/01/2026
Director/Board Member 70 03/09/2021
Director/Board Member 58 23/09/2021
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/26 Free

Founder

7,500 0.0267%
31/07/26 Free

Director

7,500 0.0267%
31/07/26 Free

Chairman

7,500 0.0267%
Change 5-day change 1-year change 3-year change Capi.($)
+10.52%-17.13%-72.48%-91.92% 19.33M
+1.76%+3.62%+49.92%+101.12% 69.69B
+2.29%+1.43%+38.39%+77.80% 61.24B
+0.68%-3.04%-14.76%+364.82% 26.77B
+0.32%+2.58%+29.26%+14.12% 26.12B
+2.97%+2.49%+0.67%-9.39% 24.07B
+1.49%+7.73%+26.85%-13.79% 20.39B
-0.83%-11.15%+169.70%+295.44% 15.72B
+1.70%+0.96%+43.37%+171.57% 14.07B
+0.17%-4.07%-9.71%+484.05% 14.03B
Average +2.12%-2.78%+26.12%+139.38% 27.21B
Weighted average by Cap. +1.49%+0.20%+36.39%+129.67%

Financials

2026 *2027 *
Net sales 2.4M 2.09M 1.98M 1.8M 3.36M 230M 3.37M 23.56M 9.11M 117M 9.02M 8.82M 374M -
Net income -19.7M -17.16M -16.24M -14.75M -27.56M -1.89B -27.7M -193M -74.79M -959M -74.01M -72.36M -3.07B -57.36M -49.96M -47.29M -42.96M -80.26M -5.49B -80.66M -563M -218M -2.79B -215M -211M -8.94B
Net Debt -149M -130M -123M -112M -209M -14.29B -210M -1.46B -566M -7.26B -560M -548M -23.25B -310M -270M -256M -232M -434M -29.69B -436M -3.04B -1.18B -15.09B -1.16B -1.14B -48.31B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.
Employees
22
Date Price Change Volume
17/09/26 US$0.6447 +10.98% 251,948
16/09/26 US$0.5809 +1.89% 505,321
15/09/26 US$0.5701 -9.91% 402,557
14/09/26 US$0.6328 -4.16% 404,676
11/09/26 US$0.6603 -5.77% 294,293
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.7740USD
Average target price
7.375USD
Spread / Average Target
+852.84%
  1. Stock Market
  2. Stocks
  3. JSPR Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!